Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Alice T. Shaw; Beow Y. Yeap; Mari Mino–Kenudson; Subba R. Digumarthy; Daniel B. Costa; Rebecca S. Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J. Mark; Scott J. Rodig; Lucian R. Chirieac; Eunice L. Kwak; Thomas J. Lynch; A. John Iafrate

doi:10.1200/jco.2009.22.6993

Key Points

The study aims to characterize clinical features and outcomes of NSCLC patients with the EML4-ALK mutation.
Analysis of clinical features in patients with EML4-ALK mutation in NSCLC.
Assessment of treatment outcomes compared to those not harboring the mutation.
Patients with EML4-ALK do not benefit from EGFR TKIs, indicating ineffective treatment.
Recommendation for directing these patients toward trials of ALK-targeted therapies.

Implication

Clinical features and outcomes are examined in patients with EML4-ALK, suggesting a need for targeted trials.

Abstract

EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics. Patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shaw et al. (2009) studied this question.

synapsesocial.com/papers/69dcc30ed4d0de07d11339c6 https://doi.org/10.1200/jco.2009.22.6993

View Full Paper

Ask AI

Bookmark

Share

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Key Points

Implication

Abstract

Discussion

Cite This Study

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of Clinical Oncology

Keep reading

More related papers

More from Journal of Clinical Oncology